García Manero Manuel*, Ceamanos Montañes Carolina, Campo Ainhoa, Peru Gema

Department of Obstetrics and Gynecology, Hospital García Orcoyen, Estella, Navarra, Spain

*Corresponding Author: García Manero Manuel, Department of Obstetrics and Gynecology, Hospital García Orcoyen, Estella, Navarra, Spain.

Received: September 14, 2022; Published: December 30, 2022

Abstract

Objective: to evaluate the effect of the combination of inositiol derivatives and lipid mediators on the metabolic and inflammatory profile of women with polycystic ovary syndrome.

Material and Methods: Experimental, prospective and longitudinal study carried out in patients diagnosed with polycystic ovary syndrome (Rotterdam criteria) without treatment or previous dietary intervention. The following nutritional preparations were administered orally daily:

• Group A: 300mg D-chiro-inositol, 1099mg myo- inositol + 30mg lipinova
• Group B: 4000 mg of myo -inositol + 30 mg of lipinova

The metabolic profile is compared before and after 4 weeks of treatment in each patient, determining the insulin levels and the HOMA index. The inflammatory profile was analyzed by determining the levels of IL-6 before and after treatment.

Results

• 41 patients with polycystic ovary syndrome subdivided into 20 from group A and 21 from group B were studied.
• Insulin levels before and after treatment were 17.9 +-9.3 SD and 10 +-4.09 SD, respectively, with statistically significant differences.
• The HOMA index pre-treatment was 4.1 +-2.1 SD and 2.1+- 1.1 SD post-treatment, with significant differences
• The level of IL-6 was pretreatment was 3.8 +- 1.5 Sd of 2.1 + -1.09 post treatment with significant differences

Conclusion: The results of the study show the positive effect of the combined administration of inositolic derivatives and pro-resolution lipid mediators on the metabolic, clinical and inflammatory profile of patients with polycystic ovary syndrome.

Keywords: Pro-Resolving Lipid Mediators; Inositol; Polycystic Ovary

References

1. Azziz R and Adashi EY. “Stein and Leventhal: 80 years on”. American Journal of Obstetrics and Gynecology 214 (2016): 247.e1-247.e11.
2. Dokras A., et al. “Gaps in knowledge amongs regarding diagnostic criteria and management of polycystic ovary syndrome”. Fertility and Sterility 107 (2017): 1380-1386.e1
3. Lizneva D., et al. “Criteria, prevalence and phenotypes of polycystic ovarian syndrome”. Fertility and Sterility 106 (2016): 6-15.
4. National Institutes of Health. “Evidence-based methodology workshop on polycystic ovary syndrome. Executive summary”. Final report (2012).
5. Lizneva D., et al. “Phenotypes and body mass in women with PCOS identified in clinical versus unselected populations: systematic review and meta-analysis”. Fertility and Sterility 106 (2016): 1510-1220.
6. Azziz R., et al. “Screening for 21-hydroxylase deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study”. Fertility and Sterility 72 (1999): 915-925.
7. Knochenhauer ES., et al. “Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study”. The Journal of Clinical Endocrinology and Metabolism 83 (1998): 3078-3082.
8. Bozdag G., et al. “The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis”. Human Reproduction 31 (2016): 2841-2855.
9. Yildiz BO., et al. “Visually scoring hirsutism”. Human Play Update 16 (2010): 51-64.
10. Treloar AE., et al. “Variation of the human menstrual cycle through reproductive life”. International Journal of Fertility 12 (1967): 77-126.
11. Lizneva D., et al. “Androgen excess: investigations and management”. Best Practice and Research Clinical Obstetrics and Gynaecology 37 (2016): 98-118.
12. Landay M., et al. “The degree of hyperinsulinemia, independent of androgen levels, is an important determinant of the severity of hirsutism in PCOS”. Fertility and Sterility 92 (2009): 643-647.
13. Brower M., et al. “The severity of menstrual dysfunction as a predictor of insulin resistance in patients with polycystic ovary syndrome”. The Journal of Clinical Endocrinology and Metabolism 98 (2013): E1967-1971.
14. Azziz R., et al. “Polycystic ovary syndrome”. Nature Reviews Disease Primers 2 (2016): 16057.
15. Nestler JE., et al. “A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome”. The Journal of Clinical Endocrinology and Metabolism 72 (1991): 83-89.
16. Nestler JE., et al. “Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using in ositolglycan mediators as the signal transduction system”. The Journal of Clinical Endocrinology and Metabolism 83 (1998): 2001-2005.
17. The International Diabetes Federation: The IDF consensus worldwide definition of metabolic syndrome (2005).
18. Ehrmann DA., et al. “PCOS/Troglitazone Study Group. Prevalence and prediction of the metabolic syndrome in women with polycystic ovary syndrome”. The Journal of Clinical Endocrinology and Metabolism 91 (2006): 48-53.
19. Lobo DR and Carina E. “The importance of diagnosing the polycystic ovary syndrome”. Annals of Internal Medicine 132 (2000): 989-93.
20. Larsen R., et al. “Williams Textbook of Endocrinology by Elsevier Science (USA)” 627-636.
21. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. “Revised 2003 Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome”. Fertility and Sterility 81 (2004): 19-25.
22. Bonora E., et al. “Prevalence of insulin resistance in metabolic disorders”. The Brunik Study ll Diabetes 47 (1998): 1643-1649.
23. Yeni-Konslrian H., et al. “Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers”. Diabetescare 23 (2000): 171-175.
24. Abraham Gnanadass S., et al. “Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update”. Archives of Gynecology and Obstetrics 3 (2021): 631-643.
25. Peng Z., et al. “Interleukin-6 Levels in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis”. PLoS One 2 (2016): e0148531.
26. Paul C., et al. “Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives”. Gynecological Endocrinology 6 (2016): 431-438.
27. Nordio M., et al. “Clinical Trial The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone”. European Review for Medical and Pharmacological Sciences 5 (2012): 575-581.
28. Facchinetti F., et al. “Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS”. European Journal of Obstetrics and Gynecology and Reproductive Biology 195 (2015): 72-76.
29. Regidor PA., et al. “Chronic Inflammation in PCOS: The Potential Benefits of Specialized Pro-Resolving Lipid Mediators (SPMs) in the Improvement of the Resolutive Response”. International Journal of Molecular Sciences 1 (2020): 384.
30. , et al. “PCOS: A Chronic Disease That Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs)”. Biomedicines 10.2 (2022): 456.
31. Serhan CN and Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology”. Nature 7503 (2014): 92-101.
32. Calder PC. “Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or pharmacology?” British Journal of Clinical Pharmacology 75 (2013): 645-662.
33. Poudyal H., et al. “Omega-3 fatty acids and metabolic syndrome: Effects and emerging mechanisms of action”. Progress in Lipid Research 50 (2011): 372-387.
34. Akinkuolie AO., et al. “Omega-3 polyunsaturated fatty acid and insulin sensitivity: A meta-analysis of randomized controlled trials”. Clinical Nutrition 30 (2011): 702-707.
35. Phelan N., et al. “Hormonal and metabolic effects of polyunsaturated fatty acids in young women with polycystic ovary syndrome: Results from a cross-sectional analysis and a
    randomized, placebo-controlled, crossover trial”. The American Journal of Clinical Nutrition 93 (2011): 652-662.
36. Rafraf M., et al. “Omega-3 fatty acids improve glucose metabolism without effects on obesity values and serum visfatin levels in women with polycystic ovary syndrome”. Journal of the American College of Nourishment 31 (2012): 361-368.
37. Unfer VA. “Deeper Assessment of ω 3-Poly-Unsaturated Fatty Acids in Polycystic Ovary Syndrome Management. Comment on Regidor et al. Chronic Inflammation in PCOS: The Potential Benefits of Specialized Pro-Resolving Lipid Mediators (SPMs) in the Improvement of the Resolutive Response”. International Journal of Molecular Sciences 22 (2021): 384.

Citation

Citation: García Manero Manuel., et al. “Polycystic Ovary Syndrome: Effect of Inositols and Lipid Mediators. Pilot Study". Acta Scientific Women's Health 5.1 (2023): 45-56.

Copyright

Copyright: © 2022 García Manero Manuel., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.